UnicoCell Biomed Co., Ltd. (TPE:6794)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
80.00
0.00 (0.00%)
At close: Mar 24, 2026

UnicoCell Biomed Income Statement

Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
30.131.8824.5914.48.18
Revenue Growth (YoY)
-5.58%29.66%70.79%76.07%105.35%
Cost of Revenue
11.1311.316.696.22.35
Gross Profit
18.9820.5717.98.25.83
Selling, General & Admin
41.634.8531.425.423.3
Research & Development
107.5488.6482.7874.9169.87
Operating Expenses
149.26123.49114.18100.3193.17
Operating Income
-130.28-102.92-96.28-92.11-87.34
Interest Expense
-1.34-1.47-1.45-1.26-0.66
Interest & Investment Income
10.17.545.790.840.08
Currency Exchange Gain (Loss)
0.020.020.010.05-
Other Non Operating Income (Expenses)
7.335.133.041.181.54
EBT Excluding Unusual Items
-114.16-91.7-88.9-91.3-86.37
Gain (Loss) on Sale of Investments
-0.67-1.79-0.1-
Gain (Loss) on Sale of Assets
-0.414.79--
Other Unusual Items
---0.05-
Pretax Income
-114.84-93.07-84.11-91.16-86.37
Net Income
-114.84-93.07-84.11-91.16-86.37
Net Income to Common
-114.84-93.07-84.11-91.16-86.37
Shares Outstanding (Basic)
6157544138
Shares Outstanding (Diluted)
6157544138
Shares Change (YoY)
6.14%6.68%29.61%10.12%6.10%
EPS (Basic)
-1.89-1.62-1.56-2.20-2.29
EPS (Diluted)
-1.89-1.62-1.56-2.20-2.29
Free Cash Flow
-96.81-66.84-81.35-78.05-85.34
Free Cash Flow Per Share
-1.59-1.17-1.51-1.88-2.27
Gross Margin
63.04%64.52%72.78%56.93%71.32%
Operating Margin
-432.77%-322.83%-391.56%-639.78%-1068.08%
Profit Margin
-381.48%-291.94%-342.06%-633.15%-1056.30%
Free Cash Flow Margin
-321.59%-209.66%-330.82%-542.15%-1043.70%
EBITDA
-116.71-82.37-76.71-76.25-71.24
EBITDA Margin
--258.35%---
D&A For EBITDA
13.5720.5619.5715.8616.1
EBIT
-130.28-102.92-96.28-92.11-87.34
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.